Apoznański Wojciech, Rysiakiewicz Jolanta, Polok Marcin, Rysiakiewicz Konrad, Siekanowicz Piotr, Hilger Tomasz, Zagierski Jan, Hilger Magdalena, Nowak Irena, Kolęda Piotr, Szydełko Tomasz
Department of Paediatric Surgery and Urology, Wroclaw Medical University, Poland.
Department of Paediatric Surgery and Traumatology, Bieganski Regional Specialist Hospital, Grudziądz, Poland.
Adv Clin Exp Med. 2015 May-Jun;24(3):505-9. doi: 10.17219/acem/36600.
Bladder cancer occurs mainly in adults. In children, younger than 10 years in particular, it is very rare.
The aim of the study is to retrospectively evaluate the efficacy of transurethral resection of the bladder tumour (TUR-BT) of transitional cell carcinoma (TCC) of the bladder in children.
Transurethral resection of the bladder tumour was performed in 7 boys aged 4 to 17 years (median 12.1 years). In all cases laboratory tests, ultrasound, and cystoscopic tumour biopsy were carried out prior to the resection. Doxorubicin was additionally instilled intravesically as one dose in two patients. The Foley catheter was left in the bladder for 1 to 4 days (median 1.85 days). The follow-up period ranged from 10 months to 10 years (median 4 years).
Papillary urothelial neoplasm of low malignant potential (PUNLMP) was diagnosed in 5 patients and urothelial papilloma in 2. Local recurrence was observed in one case two years after the resection. In all other cases complete remission was achieved.
Transitional cell carcinoma of the bladder in children is usually benign and endoscopic treatment (TUR-BT) seems to be the treatment of choice. To determine a follow-up schedule a more substantial group of children with bladder cancer should be analysed.
膀胱癌主要发生于成年人。在儿童中,尤其是10岁以下的儿童,膀胱癌非常罕见。
本研究旨在回顾性评估经尿道膀胱肿瘤切除术(TUR-BT)治疗儿童膀胱移行细胞癌(TCC)的疗效。
对7名年龄在4至17岁(中位年龄12.1岁)的男孩实施了经尿道膀胱肿瘤切除术。所有病例在切除术前均进行了实验室检查、超声检查和膀胱镜肿瘤活检。另外,两名患者膀胱内灌注了一剂阿霉素。Foley导尿管在膀胱内留置1至4天(中位时间1.85天)。随访期为10个月至10年(中位时间4年)。
5例诊断为低恶性潜能乳头状尿路上皮肿瘤(PUNLMP),2例为尿路上皮乳头状瘤。1例在切除术后两年出现局部复发。在所有其他病例中均实现了完全缓解。
儿童膀胱移行细胞癌通常为良性,内镜治疗(TUR-BT)似乎是首选治疗方法。为确定随访方案,应分析更多的儿童膀胱癌患者群体。